Drug Profile
Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma
Alternative Names: CX 2614; CX009; CX1370Latest Information Update: 28 Jun 2013
Price :
$50
*
At a glance
- Originator Krenitsky Pharmaceuticals
- Developer CeNeRx BioPharma
- Class Small molecules
- Mechanism of Action Monoamine oxidase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 28 Jun 2013 Discontinued - Preclinical for Anxiety disorders in USA (PO)
- 28 Jun 2013 Discontinued - Preclinical for Major depressive disorder in USA (PO)
- 27 Jan 2011 Preclinical development is ongoing in USA